SpliSense Granted EMA EARLY PRIME Designation for SPL84 in Cystic Fibrosis

e-PRIME recognition underscores potential of inhaled RNA therapy to address unmet need in patients with the 3849+10Kb C>T mutation Company advancing SPL84 to Phase 2b clinical study JERUSALEM, March 3, 2026 /PRNewswire/ -- SpliSense, a clinical-stage biotechnology company developing...